Literature DB >> 1111937

Medullary carcinoma of the thyroid gland.

G C Chong, O H Beahrs, G W Sizemore, L H Woolner.   

Abstract

One hundred thirty-nine surgically treated patients with medullary carcinoma of the thyroid gland (MTC) were seen in our institution between January, 1926 and December, 1973. The incidence of this tumor among all thyroid cancers was 8%. Twenty-nine patients had the familial form of MTC; they were subclassified, on the basis of the phenotype, into a group of 15 patients with Sipple syndrome (or multiple endocrine neoplasia (MEN) Type 2A) and a group of 14 patients with mucosal-neuroma phenotype (or MEN type 2B). Better survivorship was seen in the younger patients, in those with bilateral tumors, in familial MTC, and in patients whose tumor was confined to the thyroid gland at the initial surgery. The incidence of tumor recurrence was 34%. However, in those with adequate surgical treatment, the recurrence was only 23%. The 5- and 10-year survivorships were 80% and 67%, respectively. The best chance of cure lies in early diagnosis through the use of immunoreactive calcitonin measurement in family members at risk, and an aggressive surgical attack on the primary tumor and any cervical metastases.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1111937     DOI: 10.1002/1097-0142(197503)35:3<695::aid-cncr2820350323>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

Review 1.  The C cells (parafollicular cells) of the thyroid gland and medullary thyroid carcinoma. A review.

Authors:  J B Hazard
Journal:  Am J Pathol       Date:  1977-07       Impact factor: 4.307

2.  Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival.

Authors:  Isabel Peixoto Callejo; José Américo Brito; Carlos Manuel Zagalo; Jorge Rosa Santos
Journal:  Clin Transl Oncol       Date:  2006-06       Impact factor: 3.405

3.  Chronic diarrhoea--all in the bowel?

Authors:  S Gupta; C J Tibbs; M J G Farthing; R C G Pollok
Journal:  J R Soc Med       Date:  2007-08       Impact factor: 5.344

4.  Long-term outcome of reoperations for medullary thyroid carcinoma.

Authors:  Elizabeth Fialkowski; Mary DeBenedetti; Jeffrey Moley
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 5.  Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective.

Authors:  Stephen J Marx; David Goltzman
Journal:  J Bone Miner Res       Date:  2018-12-10       Impact factor: 6.741

Review 6.  The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.

Authors:  T Kusafuka; P Puri
Journal:  Pediatr Surg Int       Date:  1997       Impact factor: 1.827

7.  The parathyroid glands in multiple endocrine neoplasia type 2b.

Authors:  J A Carney; S I Roth; H Heath; G W Sizemore; A B Hayles
Journal:  Am J Pathol       Date:  1980-05       Impact factor: 4.307

8.  Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorigenesis.

Authors:  D G Wang; W H Liu; C F Johnston; J M Sloan; K D Buchanan
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

9.  Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma.

Authors:  N Neuhold; F Längle; M Gnant; U Hollenstein; B Niederle
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

10.  Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.

Authors:  Abbas K Samadi; Joseph Bazzill; Xuan Zhang; Rob Gallagher; Hauping Zhang; Rao Gollapudi; Kelly Kindscher; Barbara Timmermann; Mark S Cohen
Journal:  Surgery       Date:  2012-12       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.